Mounjaro activates both GLP-1 and GIP receptors simultaneously the first weight loss medication to do so.
SURMOUNT clinical trial data. The highest average weight loss outcomes of any approved GLP-1 medication.
One subcutaneous injection per week in-office at Aviva or self-administered at home at no extra charge.
Mounjaro is included in the Aviva 3-month weight loss program alongside 12 EvolveX sessions and 3 Morpheus8 treatments
Mounjaro activates both GLP-1 and GIP receptors simultaneously the first weight loss medication to do so.
SURMOUNT clinical trial data. The highest average weight loss outcomes of any approved GLP-1 medication.
One subcutaneous injection per week in-office at Aviva or self-administered at home at no extra charge.
Mounjaro is included in the Aviva 3-month weight loss program alongside 12 EvolveX sessions and 3 Morpheus8 treatments
APPETITE REGULATION + BLOOD SUGAR CONTROL
GLP-1 (glucagon-like peptide-1) receptor activation reduces appetite, slows gastric emptying, and improves insulin secretion in response to meals. This is the mechanism shared with semaglutide the established, well-understood foundation of GLP-1 therapy.
Appetite reduction typically felt within weeks 1–4
INSULIN SENSITIVITY + ENERGY METABOLISM
GIP (glucose-dependent insulinotropic polypeptide) receptor activation unique to tirzepatide enhances insulin sensitivity, supports fat metabolism, and appears to reduce the nausea associated with GLP-1 activation alone. This second mechanism is why tirzepatide shows greater average weight loss with a tolerable side effect profile.
Metabolic improvements measurable within 4–8 weeks
SUPERIOR COMBINED CLINICAL OUTCOME
The simultaneous activation of both receptors produces clinical results that exceed either mechanism in isolation. SURMOUNT-1 trial data shows average weight loss of ~20–22% over 72 weeks at the highest dose. For patients who want the most clinically effective GLP-1 option available, Mounjaro is currently the leading choice.
22% average body weight loss over 72 weeks · SURMOUNT-1 trial, highest dose cohort
Dual GLP-1 + GIP receptor agonist two mechanisms
22% average body weight loss (SURMOUNT trials, highest dose)
FDA-approved for weight management as Zepbound® 2023
GIP activation may reduce GLP-1 side effects for some patients
Newer generation fewer years of long-term data vs. semaglutide
Best for: patients who want the highest clinical average and are comfortable with a newer medication
Single GLP-1 receptor agonist — one mechanism
15% average body weight loss (STEP trials)
FDA-approved for weight management as Wegovy® 2021
Longer real-world track record more patient data available
Well-established safety profile since 2017 (Ozempic)
Best for: patients who want the most established option with the longest safety record
4 EvolveX body sculpting sessions per month run alongside your Mounjaro injections throughout the program. As fat reduces, EvolveX tightens the overlying skin and stimulates muscle definition. Included in the program.
Morpheus8 RF microneedling addresses the skin laxity that develops with significant weight loss on the body and face. One session per month, applied where you need it most. Included in the program.
Rapid GLP-1 weight loss can accelerate facial volume loss. Sculptra collagen biostimulation gradually rebuilds the structural support that changes with significant weight loss available as a complementary add-on.
Tirzepatide (Mounjaro / Zepbound) is a dual GLP-1 + GIP receptor agonist the first weight loss medication to activate both receptors simultaneously. Semaglutide activates only the GLP-1 receptor. The dual mechanism produces higher average clinical weight loss: 22% for tirzepatide vs.15% for semaglutide in comparative trials. Both are available at Aviva; your provider will recommend based on your health history.
SURMOUNT-1 clinical trials show average body weight loss of approximately 20–22% over 72 weeks at the highest tirzepatide dose. Individual results vary significantly based on starting weight, diet, activity level, and program adherence. Your Aviva provider will set a realistic, personalized expectation at your free consultation.
Yes. Tirzepatide was FDA-approved for chronic weight management under the brand name Zepbound in November 2023. Mounjaro is the same molecule approved for type 2 diabetes management since 2022. Aviva prescribes tirzepatide within its approved indications for weight management.
Common side effects include nausea, diarrhea, constipation, and decreased appetite most pronounced during dose escalation and typically improving as your body adjusts. The GIP mechanism in tirzepatide may reduce GI side effects compared to semaglutide alone for some patients. Serious side effects are rare and reviewed at your medical consultation.
Yes. Mounjaro comes in a pre-filled single-use pen for once-weekly subcutaneous injection. Aviva offers in-office injection administration at no extra charge, or you can self-administer at home after a technique demonstration during your first session.
Start with your free consultation. Your Aviva provider reviews your health history, confirms candidacy, recommends Mounjaro or semaglutide, and walks you through the full 3-month program including EvolveX and Morpheus8 scheduling. Enrolling through the free consultation saves you an additional $100 on program enrollment.
Mounjaro’s clinical results are the strongest of any approved GLP-1 medication. But clinical results are achieved under supervised conditions with proper dose titration, managed side effects, and consistent follow-through. At Aviva Medical Spa in Miami’s Design District, every Mounjaro patient has a licensed medical provider managing their program from start to finish. Not a chatbot, not an auto-refill service. A provider who knows your history, monitors your response, and is there when you have questions. Combined with the body sculpting and skin tightening built into the program, Aviva’s Mounjaro offering is the most complete medical weight loss experience available in Miami.
Your Glow Starts Here
Your Glow Starts Here
